Skip to main content
SpringerLink
Log in
Book cover

Volkskrankheit Asthma/COPD pp 37–49Cite as

Volkswirtschaftliche Bedeutung von Asthma und COPD

  • Chapter

Zusammenfassung

Die Kosten für die Volkskrankheiten Asthma und COPD sind beträchtlich: sie bedingen z.B. in Europa jährliche Kosten in Höhe von 56,4 Mrd. € [23]. Ein großer Anteil wird dabei durch verlorene Arbeitstage verursacht. Für das Asthma bronchiale wurden so immerhin 14.157 und für die COPD stolze 41.280 Arbeitsunfähigkeitstage pro 100.000 Einwohner und Jahr gezählt, das sind 83,8% aller durch Lungenerkrankungen in der EU anfallenden Arbeitsausfälle. Die Gesamtausgaben für Arzneimittel für alle Lungenkrankheiten betragen europaweit 6,7 Mrd. €, wovon der überwiegende Teil (ca. 95%) auf die chronischen Erkrankungen Asthma und COPD zurückzuführen ist. Außerdem entstehen in Europa durch Asthma und COPD Krankenhauskosten in Höhe von 3,4 Mrd. €. Hinzukommen volkswirtschaftliche und soziale Belastungen, die nur teilweise mit Zahlen zu messen sind. Denn die Folgen von Entwicklungsstörungen bei Kindern durch Asthma oder soziale Deprivation durch COPD werden in keiner Studie erfasst. Im folgenden Kapitel sollen zunächst die Kosten von Asthma und COPD aufgezeigt und dann auf die sozioökonomische Bedeutung dieser chronischen Lungenerkrankungen eingegangen werden.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. ATS: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease, American Thoracic Society. Am J Respir Crit Care Med. 152:S77, 1995

    Google Scholar 

  2. Arnlind MH, Nokela M, Rehnberg C, Jonsson EW: The relationship between pharmaceutical costs, disease severity, and health-related quality of life in asthmatics in Swedish primary care. J Asthma. 43:585, 2006

    Article  PubMed  Google Scholar 

  3. Birnbaum HG, Berger WE, Greenberg PE, Holland M, Auerbach R, Atkins KM, Wanke LA: Direct and indirect costs of asthma to an employer. J Allergy Clin Immunol. 109:264, 2002

    Article  PubMed  Google Scholar 

  4. Bousquet J, Bousquet PJ, Godard P, Daures JP: The public health implications of asthma. Bull World Health Organ. 83:548, 2005

    PubMed  Google Scholar 

  5. Bundesministerium für Gesundheit: Daten des Gesundheitswesens. Ausgabe 1995, Baden-Baden, Nomos Verlagsgesellschaft, 1995

    Google Scholar 

  6. Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, Connell C, Jemal A, Lee TA, Miravitlles M, Aldington S, Beasley R: Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J. 27:188, 2006

    Article  CAS  PubMed  Google Scholar 

  7. Cisternas MG, Blanc PD, Yen IH, Katz PP, Earnest G, Eisner MD, Shiboski S, Yelin EH: A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol. 111:1212, 2003

    Article  PubMed  Google Scholar 

  8. Eckerlund I, Hakansson S: Variations in resource utilization — the role of medical practice and its economic impact. Soc Sci Med. 28:165, 1989

    Article  CAS  PubMed  Google Scholar 

  9. Feenstra TL, van Genugten ML, Hoogenveen RT, Wouters EF, Rutten-van Molken MP: The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med. 164:590, 2001

    CAS  PubMed  Google Scholar 

  10. Figueras M, Brosa M, Gisbert R: El coste de la bronqutis crónica en Espana. Enfoque incidencia [The cost of chronic bronchitis in Spain. Incidence approach]. Revista Espanola de Farmacoeconomía 2:33, 1999

    Google Scholar 

  11. Global Initiative for Asthma: GINA Workshop Report, Global Strategy for Asthma management and prevention, 2002

    Google Scholar 

  12. Global Initativ for Chronic Obstuctive Lung Disease (GOLD): Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2004.

    Google Scholar 

  13. Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G: Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J. 19:61, 2002

    Article  CAS  PubMed  Google Scholar 

  14. Goldbeck L, Koffmane K, Lecheler J, Thiessen K, Fegert JM: Disease severity, mental health, and quality of life of children and adolescents with asthma. Pediatr Pulmonol. 42:15, 2007

    Article  PubMed  Google Scholar 

  15. Halpin DM, Miravitlles M: Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc. 3:619, 2006

    Article  PubMed  Google Scholar 

  16. Hilleman DE, Dewan N, Malesker M, Friedman M: Pharmacoeconomic evaluation of COPD. Chest. 118:1278, 2000

    Article  CAS  PubMed  Google Scholar 

  17. Jansson SA, Andersson F, Borg S, Ericsson A, Jonsson E, Lundback B: Costs of COPD in Sweden according to disease severity. Chest. 122:1994, 2002

    Article  PubMed  Google Scholar 

  18. Konietzko N, Kroidl R: [Curriculum Pneumologicum 2005. Part 4]. Pneumologie. 60:258, 2006

    Article  CAS  PubMed  Google Scholar 

  19. Lecheler J: [Sports for children and adolescents with asthma — risk or chance?]. Offentl Gesundheitswes. 53:486, 1991

    CAS  PubMed  Google Scholar 

  20. Lecheler J, Gauer S: [Deficits in school performance in children and adolescents with chronic asthma]. Monatsschr Kinderheilkd. 139:69, 1991

    CAS  PubMed  Google Scholar 

  21. Loddenkemper R, Gibson GJ, Sibille Y: The burden of lung disease in Europe: why a European White Book on lung disease? Eur Respir J. 22:869., 2003

    Article  CAS  PubMed  Google Scholar 

  22. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 367:1747, 2006

    Article  PubMed  Google Scholar 

  23. Lopez AD, Murray CC: The global burden of disease, 1990–2020. Nat Med. 4:1241, 1998

    Article  CAS  PubMed  Google Scholar 

  24. Lundborg CS, Wahlstrom R, Diwan VK, Oke T, Martenson D, Tomson G: Combining feedback from simulated cases and prescribing. Design and implementation of an educational intervention in primary care in Sweden. Int J Technol Assess Health Care. 15:458, 1999

    CAS  PubMed  Google Scholar 

  25. Miravitlles M, Murio C, Guerrero T, Gisbert R: Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 121:1449, 2002

    Article  PubMed  Google Scholar 

  26. Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 349:1498, 1997

    Article  CAS  PubMed  Google Scholar 

  27. Nowak D, Dietrich ES, Oberender P, Uberla K, Reitberger U, Schlegel C, Albers F, Ruckdaschel S, Welsch R: [Cost-of-illness Study for the Treatment of COPD in Germany]. Pneumologie. 58:837, 2004

    Article  CAS  PubMed  Google Scholar 

  28. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care. 46:798, 2001

    CAS  PubMed  Google Scholar 

  29. Proctor RN: Hitler, das “Rassengift — und die Spätfolgen: Süddeutsche Zeitung, 2007

    Google Scholar 

  30. Proctor RN: Cancer Wars: How politics shapes what we know and don’t know about cancer. Basic Book, 1995

    Google Scholar 

  31. Ruchlin HS, Dasbach EJ: An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics. 19:623, 2001

    Article  CAS  PubMed  Google Scholar 

  32. Rutten van-Molken MP, Feenstra TL: The burden of asthma and chronic obstructive pulmonary disease: data from The Netherlands. Pharmacoeconomics. 19:1, 2001

    Article  PubMed  Google Scholar 

  33. Rychlik R, Pfeil T, Daniel D, Pfeil B, Mast O, Thate-Waschke I, Lorenz J: [Socioeconomic relevance of acute exacerbations of chronic bronchitis in the Federal Republic of Germany. A prospective cost of illness study]. Dtsch Med Wochenschr. 126:353, 2001

    Article  CAS  PubMed  Google Scholar 

  34. Schneider S, Mohnen S, Schiltenwolf M: [“Are rich people healthier?” — Representative epidemiological data on socioeconomic group-specific disease prevalences among adults in Germany]. Dtsch Med Wochenschr. 131:1998, 2006

    Article  CAS  PubMed  Google Scholar 

  35. Schramm B, Ehlken B, Smala A, Quednau K, Berger K, Nowak D: Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-yr retrospective study. Eur Respir J. 21:116, 2003

    Article  CAS  PubMed  Google Scholar 

  36. Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J: Costs of asthma according to the degree of severity. Eur Respir J. 12:1322, 1998

    Article  CAS  PubMed  Google Scholar 

  37. Simonella L, Marks G, Sanderson K, Andrews G: Cost-effectiveness of current and optimal treatment for adult asthma. Intern Med J. 36:244, 2006

    Article  CAS  PubMed  Google Scholar 

  38. Sin DD, Stafinski T, Ng YC, Bell NR, Jacobs P: The impact of chronic obstructive pulmonary disease on work loss in the United States. Am J Respir Crit Care Med. 165:704, 2002

    PubMed  Google Scholar 

  39. Stanford RH, Shen Y, McLaughlin T: Cost of Chronic Obstructive Pulmonary Disease in the Emergency Department and Hospital: An Analysis of Administrative Data from 218 US Hospitals. Treat Respir Med. 5:343, 2006

    Article  PubMed  Google Scholar 

  40. Statistisches Bundesamt: Gesundheitsausgaben und Krankheitskosten. www.destatis, 2002

    Google Scholar 

  41. Sullivan SD: The burden of uncontrolled asthma on the U.S. health care system. Manag Care. 14:4, 2005

    PubMed  Google Scholar 

  42. Sullivan SD, Ramsey SD, Lee TA: The economic burden of COPD. Chest. 117:5S, 2000

    Google Scholar 

  43. Szucs TD, Anderhub H, Rutishauser M: The economic burden of asthma: direct and indirect costs in Switzerland. Eur Respir J. 13:281, 1999

    Article  CAS  PubMed  Google Scholar 

  44. van den Brink-Muinen A, Verhaak PF, Bensing JM, Bahrs O, Deveugele M, Gask L, Mead N, Leiva-Fernandez F, Perez A, Messerli V, Oppizzi L, Peltenburg M: Communication in general practice: differences between European countries. Fam Pract. 20:478, 2003

    Article  PubMed  Google Scholar 

  45. Van Ganse E, Laforest L, Pietri G, Boissel JP, Gormand F, Ben-Joseph R, Ernst P: Persistent asthma: disease control, resource utilisation and direct costs. Eur Respir J. 20:260, 2002

    Article  PubMed  Google Scholar 

  46. Verband DR: VDR Statistik des Jahres 1994 einschließlich Rentenwegfall, Rentenänderung/ änderung des Teilrentenanteils aktuelle Zahlen 2001: www.vdr.de. Würzburg, 1995

    Google Scholar 

  47. World Health Organization: Chronic respiratory diseases, 2005

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Universitäts-Poliklinik Bonn, Wilhelmstraße 35-37, 53111, Bonn

    Dr. med. Ansgar D. Raadts

  2. Schwerpunkts Pneumologie, Allergologie, Schlafmedizin, Medizinische Universitäts-Poliklinik Bonn, Wilhelmstraße 35-37, 53111, Bonn

    Prof. Dr. med. Uwe R. Juergens (Leiter)

Authors
  1. Dr. med. Ansgar D. Raadts
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Uwe R. Juergens
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung für Epidemiologie, Sozialmedizin und Gesundheitssystemforschung, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, 30625, Hannover

    Heidrun Lingner  & Friedrich-Wilhelm Schwartz  & 

  2. Fachklinik Allgäu, Peter-Heel-Straße 29, 87459, Pfronten-Ried

    Konrad Schultz

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Raadts, A.D., Juergens, U.R. (2007). Volkswirtschaftliche Bedeutung von Asthma und COPD. In: Lingner, H., Schwartz, FW., Schultz, K. (eds) Volkskrankheit Asthma/COPD. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-70920-6_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-70920-6_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-70919-0

  • Online ISBN: 978-3-540-70920-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation